Changes in cyclic AMP-dependent protein kinases during inhibition of mastocytoma cell growth by dibutyryl cyclic AMP
Related Experiment Videos
Abstract:
Inhibition of growth of PY815 mouse mastocytoma cells in vitro by N6,O2'-dibutyryladenosine 3',5' cyclic monophosphate (DB cyclic AMP) was accompanied by increases in intracellular cyclic AMP and histamine and minor changes in cytosolic cyclic AMP-dependent histone kinase activity. However, DEAE-cellulose chromatography revealed substantial changes in the relative proportions of the principal cyclic AMP-dependent protein kinases and in free cyclic AMP-binding protein after DB cyclic AMP treatment. The activity of cytosolic cyclic AMP-dependent protein kinase type I (PKI) decreased relative to cyclic AMP-dependent protein kinase type II (PKII) and there was an increase in a cytosol cyclic AMP-binding protein with little associated protein kinase activity. The relative changes in activity of PKI, PKII and cyclic AMP binding protein after DB cyclic AMP treatment may reflect events important in the regulation of growth and differentiation of mast cells.
Insights
N6,O2'-dibutyryladenosine 3',5' cyclic monophosphate (DB cyclic AMP) inhibited mouse mastocytoma cell growth by altering cyclic AMP-dependent protein kinase activity. Changes in protein kinase type I and type II, and cyclic AMP-binding protein suggest roles in mast cell regulation.
Area of Science:
- Cell Biology
- Biochemistry
- Pharmacology
Background:
- Cyclic AMP (cAMP) is a crucial second messenger regulating various cellular processes.
- Cyclic AMP-dependent protein kinases (PKA) mediate many of cAMP's effects.
- Understanding PKA regulation is key to understanding cell growth and differentiation.
Purpose of the Study:
- To investigate the effects of DB cyclic AMP on PY815 mouse mastocytoma cell growth.
- To elucidate the specific changes in intracellular signaling molecules, particularly cAMP and PKA, following DB cyclic AMP treatment.
- To determine the role of altered PKA activity and cAMP-binding proteins in mast cell growth regulation.
Main Methods:
- Treatment of PY815 mouse mastocytoma cells with DB cyclic AMP.
- Measurement of intracellular cAMP and histamine levels.
- Assay of cytosolic cyclic AMP-dependent histone kinase activity.
- DEAE-cellulose chromatography to analyze PKA isoforms (PKI and PKII) and cAMP-binding proteins.
Main Results:
- DB cyclic AMP inhibited mastocytoma cell growth, increased intracellular cAMP and histamine.
- Minor changes were observed in cytosolic cyclic AMP-dependent histone kinase activity.
- DEAE-cellulose chromatography revealed significant shifts in the proportions of PKA isoforms and cAMP-binding proteins.
- Specifically, a decrease in PKA type I (PKI) relative to PKA type II (PKII) and an increase in a cAMP-binding protein with low kinase activity were noted.
Conclusions:
- DB cyclic AMP-induced mastocytoma cell growth inhibition is associated with significant alterations in PKA isoform distribution and cAMP-binding protein levels.
- The observed changes in PKI, PKII, and cAMP-binding protein activity suggest their involvement in the regulation of mast cell growth and differentiation.
- These findings provide insights into the molecular mechanisms by which cAMP modulates mast cell behavior.